Azacitidine with checkpoint inhibitors for AML and MDS

Azacitidine with checkpoint inhibitors for AML and MDS

VJHemOnc

1 year
78 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
There has been growing evidence that the combination of hypomethylating agents like azacitidine with immune checkpoint inhibitors could be a highly potent treatment option in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). We interviewed Naval Daver, MD, of the MD Anderson Cancer Center, Houston, TX, at the 23rd Congress of the European Hematological Association (EHA) 2018 in Stockholm, Sweden, about his recent studies exploring this combination. He discusses the data from these trials, including NCT02397720, highlighting the key findings, as well as the close relationship between pre-therapy CD3 and CD8 presence in the bone marrow with response rate. He explains how this correlation implies that future studies could use bone marrow CD3/8 as biomarkers to predict which patients would respond best to this treatment, greatly increasing its efficacy.
Up Next Autoplay
Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
Category: Chronic Myelogenous Leukemia
1 Views
Cancer-News 13 hours
Perspectives on the Future of CML
Perspectives on the Future of CML
Category: Chronic Myelogenous Leukemia
1 Views
Cancer-News 13 hours
2019 Nobel Prize for Medicine Recipients recognized for Cancer Research  through study of von Hippel-Lindau (VHL) disease
2019 Nobel Prize for Medicine Recipients recognized for Cancer Research through study of von Hippel-Lindau (VHL) disease
Category: Acute Lymphoblastic Leukemia
1 Views
Cancer-News 13 hours
Re-evaluating TKI in CML Patients During Pregnancy
Re-evaluating TKI in CML Patients During Pregnancy
Category: Chronic Myelogenous Leukemia
1 Views
Cancer-News 13 hours
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
Category: Acute Myelogenous Leukemia
2 Views
Cancer-News 13 hours
CML and Pregnancy
CML and Pregnancy
Category: Chronic Myelogenous Leukemia
1 Views
Cancer-News 14 hours
INNATE PHARMA HIGHLIGHTS FDA-APPROVED LUMOXITI® AT ASH 2019
INNATE PHARMA HIGHLIGHTS FDA-APPROVED LUMOXITI® AT ASH 2019
Category: Acute Lymphoblastic Leukemia
3 Views
Cancer-News 14 hours
New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refrac...
New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refrac...
Category: Chronic Lymphocytic Leukemia
2 Views
Cancer-News 14 hours
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Category: Non-Hodgkin Lymphoma
4 Views
Cancer-News 14 hours
First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers
First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers
Category: News
1 Views
Cancer-News 14 hours